Published in Hepatology on January 01, 1999
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl (2012) 4.65
Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut (2002) 1.65
Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis. Am J Transplant (2015) 1.44
Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2009) 1.41
Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog (2012) 1.35
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol (2014) 1.10
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl (2012) 1.05
Hepatitis C and liver transplantation. Gut (1999) 1.03
Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS (2009) 1.00
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99
Production and characterization of monoclonal antibodies specific for a conserved epitope within hepatitis C virus hypervariable region 1. J Virol (2001) 0.94
Liver transplantation for alcoholic liver disease. World J Gastroenterol (2010) 0.91
New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis (2016) 0.91
Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut (2002) 0.89
Recurrence of hepatitis C after liver transplantation. Ann Gastroenterol (2013) 0.88
Treatment of hepatitis C virus infection. World J Gastroenterol (2007) 0.87
Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol (2012) 0.87
Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol (2009) 0.87
Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: effects on virus replication and recurrent hepatitis. World J Gastroenterol (2006) 0.82
Markers of acute rejection and graft acceptance in liver transplantation. World J Gastroenterol (2015) 0.81
Liver transplantation for hepatitis C and alcoholic liver disease. J Transplant (2010) 0.81
Initial steroid-free immunosuppression after liver transplantation in recipients with hepatitis C virus related cirrhosis. World J Gastroenterol (2004) 0.81
Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future. World J Gastroenterol (2014) 0.81
Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection. Hepat Mon (2012) 0.81
Living donor liver transplantation for hepatitis C. Surg Today (2012) 0.81
Human liver transplantation as a model to study hepatitis C virus pathogenesis. Liver Transpl (2009) 0.79
NIM811, a nonimmunosuppressive cyclosporine analogue, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. Liver Int (2007) 0.79
Liver transplantation and hepatitis C. Int J Hepatol (2012) 0.79
Hepatitis C virus recurrence in living donor liver transplant recipients. Dig Dis Sci (2004) 0.79
Living donor liver transplantation to patients with hepatitis C virus cirrhosis. World J Gastroenterol (2006) 0.79
An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation. World J Hepatol (2011) 0.78
Treatment modalities for hypersplenism in liver transplant recipients with recurrent hepatitis C. World J Gastroenterol (2009) 0.78
Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review. World J Gastroenterol (2014) 0.77
Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin. Dig Dis Sci (2011) 0.77
Hepatitis C virus-HIV-coinfected patients and liver transplantation. Curr Opin Organ Transplant (2015) 0.76
Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt. World J Gastroenterol (2007) 0.76
HCV in liver transplantation. Semin Immunopathol (2012) 0.76
Slower Fibrosis Progression Among Liver Transplant Recipients With Sustained Virological Response After Hepatitis C Treatment. Gastroenterology Res (2015) 0.75
Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients. Can J Gastroenterol Hepatol (2016) 0.75
Management of hepatitis c genotype 4 in the liver transplant setting. Saudi J Gastroenterol (2016) 0.75
Routine Laboratory Blood Tests May Diagnose Significant Fibrosis in Liver Transplant Recipients with Chronic Hepatitis C: A 10 Year Experience. J Clin Transl Hepatol (2016) 0.75
Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation? J Clin Exp Hepatol (2017) 0.75
Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators. Gut (2015) 0.75
Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Can J Gastroenterol (2006) 0.75
Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation. Transplant Direct (2015) 0.75
Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation. PLoS One (2013) 0.75
Current trends in the treatment of hepatitis C: interventions to avoid adverse effects and increase effectiveness of anti-HCV drugs. EXCLI J (2016) 0.75
Outcomes after liver transplantation for combined alcohol and hepatitis C virus infection. World J Gastroenterol (2014) 0.75
Antihepatitis C virus therapy in liver transplanted patients. Ther Clin Risk Manag (2006) 0.75
Sofosbuvir and Ribavirin for 24 Weeks Is An Effective Treatment Option for Recurrent Hepatitis C Infection After Living Donor Liver Transplantation. J Clin Exp Hepatol (2017) 0.75
Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection. Dig Dis Sci (2013) 0.75
A Bayesian Approach for Population Pharmacokinetic Modeling of Pegylated Interferon α-2a in Hepatitis C Patients. Clin Pharmacokinet (2017) 0.75
Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. J Clin Transl Hepatol (2017) 0.75
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature (2001) 7.06
Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell (1995) 4.70
Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A (1999) 3.30
Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis (2002) 3.04
HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol (2000) 2.60
Endoscopic ultrasound-guided fine-needle aspiration and trucut biopsy in the diagnosis of gastric stromal tumors: a randomized crossover study. Endoscopy (2010) 2.40
Hepatic Encephalopathy. Am J Gastroenterol (2001) 2.37
Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene (1996) 2.20
Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA (1999) 2.16
Prevalence and clinical importance of sleep apnea in the first night after cerebral infarction. Neurology (2002) 2.16
MR imaging findings in hepatic encephalopathy. AJNR Am J Neuroradiol (2008) 2.14
Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-kappaB2. J Exp Med (1997) 2.13
[A favorable response to the somatostatin analog SMS 201-995 in a patient with the carcinoid syndrome]. Rev Esp Enferm Dig (1991) 1.94
Pulmonary infection with Nocardia species: a report of 10 cases and review. Eur Respir J (1997) 1.83
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol (2001) 1.83
Insertional mutagenesis in the extreme thermophilic eubacteria Thermus thermophilus HB8. Mol Microbiol (1992) 1.81
Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology (2004) 1.77
Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology (2000) 1.72
In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob Agents Chemother (1992) 1.64
Structure, mapping, and expression of erp, a growth factor-inducible gene encoding a nontransmembrane protein tyrosine phosphatase, and effect of ERP on cell growth. Mol Cell Biol (1993) 1.62
Macrodactyly: report of eight cases and review of the literature. Pediatr Dermatol (2000) 1.59
Constitutive and inducible Rel/NF-kappa B activities in mouse thymus and spleen. Oncogene (1994) 1.59
Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro susceptibility testing of amphotericin B, flucytosine, and fluconazole against Candida albicans. Antimicrob Agents Chemother (1996) 1.58
International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother (1983) 1.52
A conserved motif in S-layer proteins is involved in peptidoglycan binding in Thermus thermophilus. J Bacteriol (1996) 1.50
Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology (1999) 1.48
Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transpl Surg (1997) 1.46
[Study of patients referred for elevated ferritin levels and/or transferrin saturation: significance of non-alcoholic fatty liver disease]. Gastroenterol Hepatol (2004) 1.40
A high-transformation-efficiency cloning vector for Thermus thermophilus. Plasmid (1999) 1.40
Onychomadesis outbreak in Valencia, Spain, June 2008. Euro Surveill (2008) 1.39
Motor pattern of the sphincter of Oddi in patients with bilioenteric shunt: a manometric study. Am J Gastroenterol (1988) 1.39
Response to treatment with interferon-alfa in patients with chronic hepatitis C and high titers of -M2, -M4 and -M8 antimitochondrial antibodies. Rev Esp Enferm Dig (1999) 1.39
[HIV related Foix-Chavany-Marie syndrome]. Neurologia (2003) 1.39
[Correlation between magnetic resonance and disability scales (EDSS and ISS) in multiple sclerosis]. Neurologia (1991) 1.39
B cells genetically deficient in the c-Rel transactivation domain have selective defects in germline CH transcription and Ig class switching. J Immunol (1997) 1.38
[Bacteremias not detected by BACTEC NR 730]. Enferm Infecc Microbiol Clin (1990) 1.38
[Efficacy of 6-mercaptopurine in the treatment of inflammatory bowel disease]. Rev Esp Enferm Dig (1995) 1.38
Effect of selective and nonselective muscarinic blockade on cholecystokinin-induced gallbladder emptying in man. Dig Dis Sci (1992) 1.38
Receiver operating characteristics curve analysis of factors predictive of nonresponse to interferon therapy in patients with chronic hepatitis C. Rev Esp Enferm Dig (2000) 1.37
Secretion and assembly of regular surface structures in Gram-negative bacteria. FEMS Microbiol Rev (2000) 1.35
Development of Thermus-Escherichia shuttle vectors and their use for expression of the Clostridium thermocellum celA gene in Thermus thermophilus. J Bacteriol (1992) 1.34
In vitro activity of ciprofloxacin against Brucella melitensis. Eur J Clin Microbiol (1984) 1.33
Expression of the chemokine N51/KC in the thymus and epidermis of transgenic mice results in marked infiltration of a single class of inflammatory cells. J Exp Med (1994) 1.33
Antigen-induced eosinophilic lung inflammation develops in mice deficient in chemokine eotaxin. Blood (1998) 1.33
Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl (2001) 1.31
Sequence of the S-layer gene of Thermus thermophilus HB8 and functionality of its promoter in Escherichia coli. J Bacteriol (1992) 1.31
A thermophilic nitrate reductase is responsible for the strain specific anaerobic growth of Thermus thermophilus HB8. Biochim Biophys Acta (1998) 1.29
Anaerobic growth, a property horizontally transferred by an Hfr-like mechanism among extreme thermophiles. J Bacteriol (1998) 1.27
Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis (2005) 1.26
Penicillin-binding protein 3 of Listeria monocytogenes as the primary lethal target for beta-lactams. Antimicrob Agents Chemother (1990) 1.25
Normalization of T2 signal abnormalities in hemispheric white matter with liver transplant. Neurology (2002) 1.25
Liver transplantation in patients with portal vein thrombosis. Liver Transpl (2001) 1.23
De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl (2001) 1.22
Development of a clinical hepatic encephalopathy staging scale. Aliment Pharmacol Ther (2007) 1.21
Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother (1994) 1.20
Induction of cell lysis in Escherichia coli: cooperative effect of nocardicin A and mecillinam. Antimicrob Agents Chemother (1982) 1.20
Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation (2006) 1.19
Binding of 125I-labeled beta-lactam antibiotics to the penicillin binding proteins of Escherichia coli. J Antibiot (Tokyo) (1984) 1.18
The deleterious effect of donor high plasma sodium and extended preservation in liver transplantation. A multivariate analysis. Transplantation (1996) 1.17
Fluconazole susceptibilities of bloodstream Candida sp. isolates as determined by National Committee for Clinical Laboratory Standards method M27-A and two other methods. J Clin Microbiol (1999) 1.17
Cloning and expression in Escherichia coli of the structural gene coding for the monomeric protein of the S layer of Thermus thermophilus HB8. J Bacteriol (1991) 1.16
Group A streptococcal bacteremia. A 10-year prospective study. Medicine (Baltimore) (1997) 1.16
Relationship between smoking and colonic involvement in inflammatory bowel disease. Rev Esp Enferm Dig (1998) 1.14
Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol (2011) 1.14
Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia. Am J Respir Crit Care Med (1999) 1.13
Developmental expression of the vav protooncogene. Cell Growth Differ (1993) 1.13
Genetic approaches to study Rel/NF-kappa B/I kappa B function in mice. Semin Cancer Biol (1997) 1.12
S-layer protein from Thermus thermophilus HB8 assembles into porin-like structures. Mol Microbiol (1993) 1.10
31-year-old woman with an enlarged tender liver. Lancet (1995) 1.10
An overview of sexually transmitted diseases. Part III. Sexually transmitted diseases in HIV-infected patients. J Am Acad Dermatol (2000) 1.09
Vascular complications after orthotopic liver transplantation: hepatic artery thrombosis. Transplant Proc (2010) 1.07
Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS (2001) 1.07
Early infections in adult patients undergoing unrelated donor cord blood transplantation. Bone Marrow Transplant (2002) 1.07
Molecular biology of S-layers. FEMS Microbiol Rev (1997) 1.06
[Invasive fungal infections in patients with blood disorders]. Med Clin (Barc) (1998) 1.06
The "target sign": is it a specific sign of CNS tuberculoma? Neuroradiology (1996) 1.06
Surface proteins and a novel transcription factor regulate the expression of the S-layer gene in Thermus thermophilus HB8. Mol Microbiol (1997) 1.06
Individual prediction of response to pneumatic dilation in patients with achalasia. Dig Dis Sci (1996) 1.05
Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol (2011) 1.04